Tauopathy
Alzheimer’s experts revise guidelines for amyloid, tau PET utilization
Revised guidelines for amyloid and tau positron emission tomography for Alzheimer’s disease and dementia state these tests should only be ordered if the results will directly impact care, like when determining treatment eligibility.
Blood-based tau pathology test for Alzheimer’s disease in development
A clinical diagnostics company and biotech firm have announced a partnership to develop a blood-based tau pathology test that would assist in the diagnosis of Alzheimer’s disease.
International group revises diagnostic guidance for Alzheimer’s
The International Working Group has updated diagnostic guidelines for Alzheimer’s disease to include individuals with normal cognition who test positive for core biomarkers indicative of disease pathology.
FDA grants fast-track designation to injectable positron emission tomography diagnostic
The FDA has granted fast-track designation to an investigational tau positron emission tomography diagnostic that can be used for a range of neurodegenerative conditions, according to the manufacturer.
Lecanemab slows progression of novel Alzheimer’s-related biomarker over 18 months
PHILADELPHIA — Treatment with lecanemab slowed the progression of a potential novel Alzheimer’s disease-related biomarker by 44% over 18 months compared with placebo, with the biomarker itself most correlating with tauopathy, data show.
Q&A: Blood-based biomarker testing ‘scientific consensus favorite’ for AD detection
Earlier this year, the FDA granted breakthrough device designation to Quanterix for its blood-based diagnostic assay to aid in the diagnosis of Alzheimer’s disease.
FDA grants breakthrough device designation to blood-based Alzheimer’s biomarker assay
The FDA has granted breakthrough device designation to a blood-based biomarker test to more quickly detect amyloid presence in individuals with suspected Alzheimer’s disease, according to the manufacturer.
Education level correlated with functional decline in Black adults with high tau levels
Higher education levels may protect against cognitive and functional difficulties for Black individuals with high levels of tau, indicating Alzheimer’s pathology, according to research from the Journal of Alzheimer’s Disease.
Plasma p-tau assay highly accurate in identifying Alzheimer’s-related pathology
A plasma phosphorylated-tau217 assay demonstrated a high degree of accuracy in identifying biomarkers consistent with Alzheimer’s disease-related pathology, according to research from JAMA Neurology.
Donanemab slows disease progression, reduces amyloid in early symptomatic Alzheimer’s
Compared with placebo, donanemab slowed disease progression and reduced amyloid presence at 76 weeks for carriers and noncarriers of the APOE ε4 allele in early symptomatic Alzheimer’s disease, according to data presented at CTAD.